Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE7A | Q13946 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SIGMAR1 | Q99720 | 4/20 | 0.36 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 3/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.32 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL724768 | 0.95 | POLB (0.40) | PDE7APOLBHSD17B10MEN1KMT2A | |
| SCHEMBL724860 | 0.93 | POLB (0.43) | PDE7APOLBHSD17B10MEN1KMT2A | |
| SCHEMBL883727 | 0.90 | PDE7A (0.35) | PDE7APOLBHSD17B10MEN1KMT2A | |
| SCHEMBL3637362 | 0.86 | HRH3 (0.36) | SIGMAR1HRH3 | |
| SCHEMBL18563077 | 0.82 | PDE7A (0.37) | PDE7APOLBHSD17B10HRH3 | |
| SCHEMBL725303 | 0.82 | DPP4 (0.38) | SIGMAR1HRH3 | |
| SCHEMBL724375 | 0.82 | DPP4 (0.38) | SIGMAR1HRH3 | |
| SCHEMBL785385 | 0.82 | ALDH1A1 (0.37) | POLB | |
| SCHEMBL16612268 | 0.82 | KDM4E (0.40) | PDE7APOLBMEN1KMT2A | |
| SCHEMBL1999934 | 0.82 | DPP4 (0.38) | SIGMAR1HRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563043-A | SUBSTITUTED PYRIDINES AS INHIBITORS OF DNMT1 | 葛兰素史密斯克莱知识产权发展有限公司 | 2019-04-02 | — | — | CN | disclosed |
| EP-1669350-B1 | PIPERIDINE DERIVATIVES | MSD KK (JP) | 2012-02-29 | — | — | EP | disclosed |
| CN-102046624-A | Tetrahydronaphthyridines and aza derivatives thereof as histamine H3 receptor antagonists | EVOTEC AG | 2011-05-04 | — | — | CN | disclosed |
| US-20110046130-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-02-24 | — | — | US | disclosed |
| US-20110046130-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC AG (DE) | 2011-02-24 | — | — | US | disclosed |
| EP-2268638-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | Evotec AG (DE) | 2011-01-05 | — | — | EP | disclosed |
| US-7834182-B2 | histamine H3 receptor antagonists; metabolic disorders, sleep disorders, cardiovascular disorders, alcoholism, drug addiction, memory disorders, Alzheimer's, Parkinson's disease; 2-(4-piperidinylpiperidinyl)pyrimidine compounds such as 2-[(4-piperidin-1-yl)piperidin-1-yl]-5-(3-pyridyl)pyrimidine | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2010-11-16 | — | — | US | disclosed |
| WO-2010052222-A1 | (DIHYDRO)NAPHTHYRIDINONE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
| WO-2010052222-A1 | (DIHYDRO)NAPHTHYRIDINONE DERIVATIVES AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2010-05-14 | — | — | WO | disclosed |
| WO-2009121812-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-10-08 | — | — | WO | disclosed |
| WO-2009121812-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | EVOTEC NEUROSCIENCES GMBH (DE) | 2009-10-08 | — | — | WO | disclosed |
| US-20090203710-A1 | Novel piperidine derivative | MSD K.K. (JP) | 2009-08-13 | — | — | US | disclosed |
| US-7547693-B2 | Such as N-methyl-N-(1-methylpiperidin-4-yl)-4-[4-(piperidin-1-yl)piperidin-1-yl]benzamide; histamine h3-antagonists | BANYU PHARMACEUTICAL CO. LTD. (JP) | 2009-06-16 | — | — | US | disclosed |
| US-20070105901-A1 | Novel piperidine derivative | MSD K.K. (JP) | 2007-05-10 | — | — | US | disclosed |
| EP-1669350-A1 | NOVEL PIPERIDINE DERIVATIVE | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2006-06-14 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110046130-A1 | TETRAHYDRONAPHTHYRIDINES AND AZA DERIVATIVES THEREOF AS HISTAMINE H3 RECEPTOR ANTAGONISTS | HRH4, HRH3, HRH1 | PDE7A 638/4885POLB 3946/4885HSD17B10 4205/4885 |
| US-20070105901-A1 | Novel piperidine derivative | HRH3, OPRM1, OPRK1 | PDE7A 3693/4885POLB 2791/4885HSD17B10 2510/4885 |
| US-20090203710-A1 | Novel piperidine derivative | HRH3, OPRM1, HRH4 | PDE7A 3811/4885POLB 2903/4885HSD17B10 2391/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.